

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 20-323/S-021

CHEMISTRY REVIEW(S)

NDA 20-323/S-021

Vivelle® (estradiol transdermal system) 0.0375, 0.05, 0.75, 0.1 mg/day

Novartis Pharmaceutical Corporation

Chemistry Review

No changes were made to the Chemistry, Manufacturing and Quality Control sections of the NDA in this application. No chemistry review was needed.



ISI 2/12/00

ISI 2/14/00

APPEARS THIS WAY
ON ORIGINAL